SEC
SlamSEC
SearchBrowseEarnings

NEKTAR THERAPEUTICS

Nasdaq:NKTR
Pharmaceutical Preparations·SAN FRANCISCO, CA
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

Summary Financials

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California.

Revenue
$98.4M
+9.2% YoY
FY 2025
Adj. EBITDA
-$98.2M
-99.8% margin
FY 2025
Net Income
-$119.0M
-120.9% margin
FY 2025
EPS (Diluted)
-$8.68
FY 2025
Stock Price
$71.16
-3.0%
2026-03-13
52W Range
$6.48 – $75.67
P/E Ratio
-8.2x
Market Cap
$2.0B
Cash
$44.3M
FY 2025
Total Debt
—
Net Cash
$44.3M
FY 2025
Enterprise Value
$2.0B
Debt / EBITDA
0.5x
FY 2025
EV / EBITDA
-20.3x
Employees
—